Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells

被引:0
作者
Qing He
Ning Song
Huamin Xu
Rong Wang
Junxia Xie
Hong Jiang
机构
[1] Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders and State Key Disciplines: Physiology,Department of Physiology
[2] Medical College of Qingdao University,undefined
来源
Journal of Neural Transmission | 2011年 / 118卷
关键词
Parkinson’s disease; Lewy body; Alpha-synuclein; Ferric iron;
D O I
暂无
中图分类号
学科分类号
摘要
Increased nigral iron levels and intracytoplasmic Lewy bodies (LBs) in the degenerating neurons are found in Parkinson’s disease (PD). Whether LBs formation is involved in the toxicity of iron is largely unknown. In the present study, we observed that the toxicity of ferric iron was enhanced when SK-N-SH cells were overexpressed with wild-type alpha-synuclein. The mitochondrial transmembrane potential (Δψm) and cell viability were decreased in these cells, while the intracellular reactive oxygen species (ROS) were increased, compared with that of control. More aggregated alpha-synuclein was observed in these cells. However, while silencing the expression of alpha-synuclein in SK-N-SH cells with siRNA, iron-induced toxicity could be partially alleviated, indicated by the returned Δψm and cell viability and reduced ROS formation compared with that of control. No alpha-synuclein aggregation could be observed in these cells. The results suggest that alpha-synuclein aggregation was involved in the toxicity of iron to SK-N-SH neuroblastoma cells. Targeting the aggregation of alpha-synuclein might provide a therapeutic strategy for PD in the future.
引用
收藏
页码:397 / 406
页数:9
相关论文
共 238 条
[1]  
Berg D(2006)Iron metabolism in Parkinsonian syndromes Mov Disord 21 1299-1310
[2]  
Hochstrasser H(2005)Snaring the function of alpha-synuclein Cell 123 359-361
[3]  
Bonini NM(2006)Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients Mov Disord 21 1703-1708
[4]  
Giasson BI(2005)Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments J Biol Chem 280 9678-9690
[5]  
Chiba-Falek O(2003)Molecular pathways of neurodegeneration in Parkinson’s disease Science 302 819-822
[6]  
Lopez GJ(1989)Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease J Neurochem 52 1830-1836
[7]  
Nussbaum RL(1993)Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia Adv Neurol 60 273-281
[8]  
Cole NB(2007)The 5′-untranslated region of Parkinson’s disease alpha-synuclein messengerRNA contains a predicted iron responsive element Mol Psychiatry 12 222-223
[9]  
Murphy DD(2005)Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion J Neurochem 95 79-88
[10]  
Lebowitz J(2000)Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology Am J Pathol 157 361-368